- Home
- TARA vs LXRX Comparison
TARA vs LXRX Comparison
Compare TARA & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARA
- LXRX
- Stock Information
- Founded
- TARA N/A
- LXRX 1995
- Country
- TARA United States
- LXRX United States
- Employees
- TARA N/A
- LXRX N/A
- Industry
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- TARA Health Care
- LXRX Health Care
- Exchange
- TARA Nasdaq
- LXRX Nasdaq
- Market Cap
- TARA 136.3M
- LXRX 124.4M
- IPO Year
- TARA N/A
- LXRX 2000
- Fundamental
- Price
- TARA $4.01
- LXRX $0.46
- Analyst Decision
- TARA Strong Buy
- LXRX Buy
- Analyst Count
- TARA 4
- LXRX 4
- Target Price
- TARA $22.67
- LXRX $3.67
- AVG Volume (30 Days)
- TARA 223.1K
- LXRX 30.7M
- Earning Date
- TARA 03-05-2025
- LXRX 03-06-2025
- Dividend Yield
- TARA N/A
- LXRX N/A
- EPS Growth
- TARA N/A
- LXRX N/A
- EPS
- TARA N/A
- LXRX N/A
- Revenue
- TARA N/A
- LXRX $31,081,000.00
- Revenue This Year
- TARA N/A
- LXRX N/A
- Revenue Next Year
- TARA N/A
- LXRX $101.91
- P/E Ratio
- TARA N/A
- LXRX N/A
- Revenue Growth
- TARA N/A
- LXRX 2481.48
- 52 Week Low
- TARA $1.60
- LXRX $0.28
- 52 Week High
- TARA $10.48
- LXRX $2.45
- Technical
- Relative Strength Index (RSI)
- TARA 43.01
- LXRX 50.39
- Support Level
- TARA $4.41
- LXRX $0.32
- Resistance Level
- TARA $4.63
- LXRX $0.71
- Average True Range (ATR)
- TARA 0.27
- LXRX 0.06
- MACD
- TARA -0.02
- LXRX 0.03
- Stochastic Oscillator
- TARA 5.30
- LXRX 36.95
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.